Conference program

Location: Hotel Suisse Majestic

Sunday, May 25th 2025 | Monday, May 26th 2025 | Tuesday, May 27th 2025

Detailed program with exact times

Sunday, May 25^th 2025

14:00 – 16:00	Pre-conference Workshop Managing Competing Priorities in BD&L: Insights from Behavioral Science Jeffrey Herman Co-founder of Leadership Advisory Partners more details
15:30 onwards	Conference Registration / Check-In
16:00 - 17:00	Welcome Coffee & Networking
17:00 - 18:45	Key Note Infectious Partnerships David Veitch, CEO at Basilea Pharmaceutica Key Note Transformational Partnerships: Crafting Deals That Drive Strategic Change Konstantina Katcheves, SVP, Global Business Development for Innovative Medicines at Teva Pharmaceuticals
18:45 - 19:00	Ice-breaker Swiss HLG Board Members
19:00 - 21:00	Kick-off dinner
21:00 - onwards	Networking with peers

Monday, May 26^th 2025

07:00	Voluntary pre-conference morning run (meet at reception)
08:30 – 09:00	Swiss HLG General Assembly – members by invitation
09:00 - 09:05	Welcome & housekeeping Intro: External drivers of portfolio strategy
09:05 - 12:10	Opening Key Note Paying for Innovation: The New Rules of Biopharma Commercialization Jeffrey Berkowitz, CEO at Real Endpoints All change: why biopharma portfolio-builders should question their assumptions Melanie Senior, Biopharma writer for Nature Biotechnology, Evaluate Pharma, IN VIVO Navigating EU Pharmaceutical Legislative Change: Recent Developments and Emerging Challenges Sarah Thomae, Head Legal Patient Safety & Global Drug Development Transactions The new pan-EU HTA process: how Joint Clinical Assessments should feature in BD thinking Sian Tanner, Principal, Value and Payer Evidence Consulting at IQVIA
12:10 - 13:35	Lunch
13:35 - 16:55	Intro: Managing a sustainable portfolio through deal-making Managing a portfolio of minority stakes – the view from venture capital Karen Wagner, General Partner at Ysios Capital Juergen Eckhardt, EVP, Head of Leaps by Bayer and Head of Pharma Business Development & Licensing From Project to Portfolio: Building and Shaping a Product Pipeline Kelvin Stott, Founder & CEO at Amporin Pharmaceuticals Unlocking Innovation: Exploring Creative Deal Structures to Secure a Robust In-Licensing Oncology Pipeline Frédéric Levy, CSO, Head of External & Internal Innovation at Debiopharm Strategic Divestment/Acquisition of Pharma Products: Optimizing Portfolio for Growth Philippe Beaupere, Chief Corporate Development Officer at Substipharm Jean-Marc Séquier, Corporate Business & Development, Head of Divestments at Novartis
19:00	Swiss HLG networking dinner
21:45 - onwards	Networking with peers

Tuesday, May 27^th 2025

07:00	Voluntary pre-conference morning run (meet at reception)
09:00 - 09:05	Welcome & Housekeeping Intro: Navigating the Unexpected: Adapting Your Portfolio Strategy
09:05 - 12:20	Genmab: A 25-year Journey From Danish Start-up to Commercial Biotech Peter Louwagie, Senior Vice President of Corporate Development/M&A & BD&L at Genmab Pioneering DARPin Therapeutics for Patients, with Partners – Navigating uncertainty and leveraging opportunities Laura Jeanbart, Director of Portfolio Management & Communications at Molecular Partners How to strengthen the path to success – as a CDMO in a changing environment. Marianne Spaene, Chief Business Officer at Siegfried Holding AG Key Note Reassessing the U.S. Landscape for Life Sciences: Implications for Deal-Making Murray Aitken, Executive Director at IQVIA Institute for Human Data Science Closing Key Note The Role of Business Development in Building Strategic and Resilient Portfolios Isabel Afonso, Chief Executive Officer at Arcera
12:20 - 12:30	Closing remarks
12:30 - 13:30	Farewell Lunch & Networking